TY - JOUR
T1 - Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia
AU - Mizutani, Motonori
AU - Takami, Akiyoshi
AU - Hara, Masahiko
AU - Mizuno, Shohei
AU - Yanada, Masamitsu
AU - Chou, Takaaki
AU - Uchiyama, Hitoji
AU - Ohashi, Kazuteru
AU - Miyamoto, Toshihiro
AU - Ozawa, Yukiyasu
AU - Imataki, Osamu
AU - Kobayashi, Naoki
AU - Uchida, Naoyuki
AU - Kanamori, Heiwa
AU - Kamimura, Tomohiko
AU - Eto, Tetsuya
AU - Onizuka, Makoto
AU - Tanaka, Junji
AU - Atsuta, Yoshiko
AU - Yano, Shingo
PY - 2017/9
Y1 - 2017/9
N2 - Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P =.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P =.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.
AB - Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P =.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P =.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.
UR - http://www.scopus.com/inward/record.url?scp=85021069069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021069069&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2017.05.008
DO - 10.1016/j.bbmt.2017.05.008
M3 - Article
C2 - 28533061
AN - SCOPUS:85021069069
VL - 23
SP - 1447
EP - 1454
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 9
ER -